Adjuvant therapy of primary breast cancer: A review of key findings from the 7th International Conference, St. Gallen, February 2001

Oncologist

Volumn 6, Issue 4, 2001, Pages 376-385

  Aapro, M S ^a  

^a CLINIQUE DE GENOLIER   (Switzerland)

Author keywords

Adjuvant chemotherapy; Consensus; Neoadjuvant chemotherapy; Primary breast cancer; St. Gallen

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE ANTIBIOTIC AGENT; AROMATASE INHIBITOR; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; LETROZOLE; MELPHALAN; PACLITAXEL; PLASMINOGEN ACTIVATOR; PROTEIN P53; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADVANCED CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER RISK; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; GENE MUTATION; HUMAN; MASTECTOMY; ONCOGENE NEU; PRIORITY JOURNAL; RISK FACTOR;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; FEMALE; HUMANS; RADIOTHERAPY, ADJUVANT;

EID: 0034873706     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-4-376     Document Type: Conference Paper

References (68)

1. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years
2. The evolution of paradigms for the management of breast cancer: A personal perspective
3. Systemic chemotherapy as an adjuvant to surgery in the treatment of breast cancer
4. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women
5. Tamoxifen for early breast cancer: An overview of the randomised trials
6. Malignant tumors of the breast
7. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
8. Features that predict responsiveness to chemotherapy and endocrine therapies
9. A review of the National Institutes of Health (NIH) Consensus Development Conference on Adjuvant Therapy of Breast Cancer
10. Dissemination risk index based on plasminogen activator system components in primary breast cancer
11. A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd
12. Best types of endocrine treatments
13. Five versus more than five years tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
14. Ovarian ablation in early breast cancer: Overview of the randomised trial
15. The emerging role of hormonal ablation as adjuvant therapy in node + and node - pre/perimenopausal patients
16. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
17. Effects of radiotherapy surgery in early breast cancer An overview of the randomized trials
18. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII
19. Best types of adjuvant chemotherapy
20. Polychemotherapy for early breast cancer: An overview of the randomised trials
21. Best timing and duration of adjuvant chemotherapy
22. The use of anthracyclines and taxanes in the adjuvant therapy of breast cancer
23. Sequential (seq) dose dense (DD) doxorubicin (A) followed by paclitaxel (P) followed by cyclophosphamide (C) is less toxic than A followed by concurrent (Con) T + C as adjuvant therapy in resected node positive (+) breast cancer (NPBC)
24. Taxane-based three-drug combination in metastatic and adjuvant treatment of breast cancer
25. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group
26. Role of paclitaxel in adjuvant therapy of operable breast cancer: Preliminary results of prospective randomized clinical trial
27. Taxane/anthracycline combinations: Setting a new standard in breast cancer?
28. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
29. Sequence dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer
30. Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic
31. Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin + paclitaxel (A + T) as first-line therapy for metastatic breast cancer: An intergroup trial
32. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer
33. North American Adjuvant Breast Cancer Trials
34. Improved disease-free survival (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC)
35. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma
36. First-line high-dose sequential chemotherapy with RG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: Toxicity and response (PEGASE 02 trial)
37. The impact of conventional plus high dose chemotherapy with autologous bone marrow transplantation on hematologic toxicity during subsequent local-regional radiotherapy for breast cancer
38. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer
39. Optimal doses of chemotherapy in adjuvant therapy of breast cancer
40. Current and planned clinical trials with trastuzumab (Herceptin)
41. Taxotere, cisplatin and Herceptin (TCH) in first-line HER2 positive metastatic breast cancer (MBC) patients, a phase II pilot study by the Breast Cancer International Research Group (BCIRG 101)
42. Phase II pilot study of Herceptin combined with Taxotere and carboplatin (TCH) in metastatic breast cancer (MBC) patients overexpressing the HER2-neu proto-oncogene: A pilot study of the UCLA Network
43. Neoadjuvant therapy in breast cancer: Can we define its role?
44. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18
45. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer
46. Prediction of response to primary chemotherapy for operable breast cancer
47. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre
48. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomised trial: S6
49. Breast tumour response to primary chemotherapy predicts local and distant control as well as survival
50. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer
51. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors
52. Docetaxel (TXT) plus doxorubicin (DOX) as neoadjuvant chemotherapy (NCT) in locally advanced inoperable stage III breast cancer (LAIBC)
53. Primary (neoadjuvant) chemotherapy with docetaxel
54. Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer
55. Recently initiated studies: Neoadjuvant treatments in the next century
56. Primary chemotherapy in the treatment of breast cancer
57. 6 Cycles of FEC 100 vs 6 cycles of epirubicin-docetaxel (ED) as neoadjuvant chemotherapy in operable breast cancer patients (pts): Preliminary results of a randomized phase II trial of GIREC S01
58. High pathological complete response (pCR) after neoadjuvant chemotherapy with doxorubicin and docetaxel in locally advanced breast cancer
59. Phase II study of doxorubicin and docetaxel as neoadjuvant therapy for women with stage IIb or III breast cancer
60. Standards of radiation after surgery
61. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomized trials
62. Radiation in the context of multidisciplinary approaches: Locally advanced diseases
63. The role of radiotherapy in the management of operable locally advanced breast carcinoma: Results of a randomized trial by the Eastern Cooperative Oncology Group
64. Breast cancer chemoprevention - Quo vadis?
65. Novel adjuvant treatments: Vaccines in breast cancer